title: Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine.
abstract: Catatonia is characterized by the predominance of psychomotor abnormalities and shares many clinical, biological and treatment response features with the neuroleptic malignant syndrome (NMS), a rare adverse reaction to psychoactive medications. It has been advocated that the two conditions should be placed along the same spectrum of disorders. A case of a 49-year-old woman, who developed NMS while on low dose clozapine soon after recovering from catatonia, is presented. The potential relationship between catatonia and NMS is discussed in the light of the existing literature, and attention is drawn to the risk for clozapine-induced NMS in catatonic patients.
authors: Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece. Thomas.Paparrigopoulos@iop.kcl.ac.uk
authors: Thomas
authors: T
authors: Paparrigopoulos
authors: Elias
authors: E
authors: Tzavellas
authors: Panagiotis
authors: P
authors: Ferentinos
authors: Iraklis
authors: I
authors: Mourikis
authors: John
authors: J
authors: Liappas
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002389:Catatonia / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy; D012307:Risk Factors; D012560:Schizophrenia, Catatonic / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine